How to Manage Estrogen on TRT

Your testosterone goes up. A few weeks later, your estradiol comes back elevated on labs. Your provider writes you a prescription for anastrozole. This is the standard sequence at most TRT clinics, and it skips the most important question: why is the conversion elevated in the first place?

To understand the answer, you need to understand the full system first.

Your body makes testosterone, and some of that testosterone gets converted into estradiol by an enzyme called aromatase, which is a protein that drives a three-step chemical reaction turning androgens into estrogens. In men, roughly 80% of circulating estradiol comes from this peripheral conversion happening in your tissues, with the remaining 20% coming directly from the testes. That ratio matters because it means estrogen production in men is almost entirely determined by what is happening in the body's tissues, not just the testes.

The tissue where most of this conversion happens is adipose tissue, meaning body fat.

Aromatase expression in fat tissue is driven by a specific gene promoter called promoter I.4, and that promoter responds to glucocorticoids, inflammatory cytokines, and something called TNF-alpha, which is a signaling molecule released during systemic inflammation. Weight gain and chronic inflammation both turn that promoter up, which means more aromatase enzyme gets produced, which means more testosterone gets converted to estradiol. Research from 2015 confirmed this in male adipose tissue specifically, and more recent data shows that men with obesity have measurably higher aromatase expression in their fat compared to lean men. The feedback loop this creates is worth noting: more fat drives more estrogen, and estrogen can promote further fat storage.

So body fat is one driver. But it is not the only one.

Injection frequency is a driver that most clinics ignore completely, and the mechanism here is straightforward. Aromatase conversion is what is called substrate-driven, meaning the more raw material you give the enzyme, the more output it produces. When you inject a full week's worth of testosterone cypionate in one shot, your blood testosterone spikes hard in the first 24 to 48 hours, and then estradiol follows about one to two days behind that peak as aromatase works through the bolus. You get a large peak of both hormones, followed by a significant trough by day seven.

Testosterone cypionate has an elimination half-life of approximately 4.5 days and a mean residence time of around 8.5 days. That pharmacokinetic profile means weekly injections produce a peak-to-trough swing that is far wider than the body's natural daily production of roughly 6 to 7 milligrams of testosterone per day. Splitting that same weekly dose into two injections reduces peak-to-trough variance by approximately 30%. Daily injection flattens it further. The total dose stays the same, so the total weekly estrogen production may be similar, but you eliminate the spikes that drive acute symptoms like water retention, nipple sensitivity, and mood instability.

This distinction matters because those symptoms are often what drives providers to prescribe an aromatase inhibitor in the first place.

Beyond body fat and injection frequency, other drivers include total dose (more testosterone means more substrate for conversion), alcohol (which directly increases aromatase activity), insulin resistance (which affects aromatase expression and also alters SHBG, changing how much free testosterone is available), chronic stress and elevated cortisol (which activate that same promoter I.4 pathway in adipose tissue), poor sleep (which elevates both cortisol and inflammatory cytokines), and genetic variation in the CYP19A1 gene, which codes for aromatase and varies meaningfully between individuals.

Now here is why this matters more than it might seem.

Estrogen is not a problem to suppress in men. It is a hormone that does active, measurable work. Estradiol levels are more strongly associated with bone mineral density, bone turnover markers, and bone loss rates in adult men than testosterone levels are. Men with aromatase deficiency develop osteopenia and fail to close their growth plates. A double-blind randomized trial from 2009 gave 69 older men one milligram of anastrozole daily for twelve months and found significant spine bone mineral density loss in the anastrozole group at twelve months, with estradiol declining from approximately 15 to 12 pg/mL. That is a modest estrogen reduction producing measurable bone loss in one year.

The 2013 NEJM study goes further. Four hundred healthy men aged 20 to 50 had their natural testosterone production suppressed, then were given exogenous testosterone at varying doses, with or without anastrozole to block aromatization. The researchers could isolate what estrogen deficiency did on its own, independent of testosterone. When aromatase was blocked, sexual desire declined significantly (P less than 0.001), erectile function declined (P equals 0.022), and subcutaneous fat area increased two to three times compared to groups where estrogen was preserved. Testosterone was present the whole time. The estrogen was blocked. And the symptoms looked like hypogonadism anyway.

This is the clinical trap that gets repeated constantly. A patient on weekly testosterone injections develops elevated estradiol symptoms. The clinic prescribes anastrozole. The patient now oscillates between too-high estrogen from large injection peaks and too-low estrogen from aromatase suppression, experiencing side effects in both directions, and the underlying drivers never get addressed.

The practical path is to start with testing that actually works. Standard immunoassay estradiol tests in men can cross-react with other steroids and produce inaccurate readings. The test you want is called LC-MS/MS, which stands for liquid chromatography tandem mass spectrometry, and it is the gold standard for measuring estradiol in men because it separates and identifies the specific molecule rather than relying on antibody binding that can misfire. Reasonable targets for most men on standard TRT doses are roughly 20 to 35 pg/mL, with 40 to 60 being acceptable at higher doses if symptoms are absent.

Once you know where your levels actually are, work the drivers before reaching for an aromatase inhibitor. Adjust injection frequency first because the pharmacokinetic mechanism is well-established even if a dedicated randomized trial comparing weekly versus daily injections on estradiol outcomes does not exist yet. Address body composition, alcohol intake, sleep, and inflammatory load. Revisit total dose. An AI may occasionally be warranted after all of that, but using it as the first response means blocking an enzyme that is doing legitimate physiological work in your bones, cardiovascular system, and brain because the conditions driving conversion were never examined.

The problem was never that your body converts testosterone to estrogen. The problem was the conditions that were driving that conversion higher than they needed to be.

---

References

1. Finkelstein JS, Lee H, Burnett-Bowie SA, et al. 2013. Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men. New England Journal of Medicine, 36911, 1011-1022. Source
2. Burnett-Bowie SM, McKay EA, Lee H, Leder BZ. 2009. Effects of Aromatase Inhibition on Bone Mineral Density and Bone Turnover in Older Men with Low Testosterone Levels. Journal of Clinical Endocrinology and Metabolism, 9412, 4785-4792. Source
3. Pastuszak AW, et al. 2022. Pharmacokinetics of Testosterone Cypionate Delivered via Subcutaneous Autoinjector. Andrology. Source
4. Chand AL, et al. (2015). Weight gain and inflammation regulate aromatase expression in male adipose tissue. Journal of Steroid Biochemistry and Molecular Biology.
5. Bhasin S, Brito JP, Cunningham GR, et al. (2018). Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. JCEM, 103(5), 1715-1744.

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness